What is the recommended treatment for shingles (herpes zoster)?

Treatment of Shingles (Herpes Zoster)

For uncomplicated shingles, start oral valacyclovir 1000 mg three times daily or acyclovir 800 mg five times daily within 72 hours of rash onset and continue until all lesions have completely scabbed over. 1, 2, 3

First-Line Oral Antiviral Therapy

Initiate treatment as soon as possible—ideally within 72 hours of rash appearance—to reduce acute pain, accelerate healing, and prevent postherpetic neuralgia. 1, 2, 3

Recommended Oral Regimens

• Valacyclovir 1000 mg orally three times daily for 7–10 days is preferred due to superior bioavailability and less frequent dosing, which improves adherence 1, 2, 3
• Acyclovir 800 mg orally five times daily for 7–10 days remains effective but requires more frequent dosing 1, 2, 3
• Famciclovir 500 mg orally three times daily for 7 days offers comparable efficacy with better bioavailability 1, 3

Critical Treatment Endpoint

• Continue antiviral therapy until all lesions have completely scabbed, not just for an arbitrary 7-day period—this is the key clinical endpoint 1, 2
• Treatment duration may need extension beyond 7–10 days if new lesions continue to form or existing lesions remain active 1

When to Escalate to Intravenous Therapy

Switch to intravenous acyclovir 10 mg/kg every 8 hours for any of the following high-risk scenarios: 1, 3

• Disseminated herpes zoster (≥3 dermatomes, visceral involvement, or hemorrhagic lesions) 1
• Severe immunosuppression (active chemotherapy, HIV with low CD4 count, organ transplant recipients) 1, 3
• Facial or ophthalmic involvement with risk of cranial nerve complications 1
• Central nervous system complications (encephalitis, meningitis, Guillain-Barré syndrome) 1
• Lack of clinical improvement after 7–10 days of appropriate oral therapy, suggesting possible acyclovir resistance 1

IV Therapy Duration and Monitoring

• Continue IV acyclovir for a minimum of 7–10 days and until all lesions have completely scabbed 1
• Monitor renal function at initiation and once or twice weekly during IV therapy; adjust dosing for renal impairment 1
• Consider temporary reduction or discontinuation of immunosuppressive medications in disseminated cases if clinically feasible 1

Special Populations and Situations

Immunocompromised Patients

• High-dose IV acyclovir 10 mg/kg every 8 hours is the treatment of choice for severely immunocompromised hosts with any VZV infection 1
• Immunocompromised patients may develop new lesions for 7–14 days and heal more slowly, requiring extended treatment courses 1
• For uncomplicated herpes zoster in mildly immunocompromised patients, oral valacyclovir or acyclovir may be used with close monitoring 1

Facial and Ophthalmic Involvement

• Facial zoster requires urgent antiviral therapy due to risk of ophthalmic complications and cranial nerve involvement 1
• Elevate the affected area to promote drainage of edema and inflammatory substances 1
• Keep skin well hydrated with emollients to prevent dryness and cracking 1

Pregnant Patients

• For serious VZV-related complications such as pneumonia in pregnancy, initiate intravenous acyclovir 1

Acute Pain Management

First-Line Analgesics

• Over-the-counter analgesics such as acetaminophen and ibuprofen are recommended for acute pain relief in otherwise healthy adults 1
• Application of topical ice or cold packs can reduce pain and swelling during the acute phase 1

Neuropathic Pain Adjuncts

• Gabapentin is the first-line oral agent for acute neuropathic pain, titrated up to 2400 mg per day in divided doses 1, 2
• Pregabalin may be added for patients with inadequate pain control on gabapentin alone 1, 2
• Capsaicin 8% patch applied for 30 minutes can provide analgesia lasting at least 12 weeks for chronic neuropathic pain 1

Corticosteroid Considerations

• Prednisone may be used as adjunctive therapy in select cases of severe, widespread shingles to alleviate short-term pain 1, 2
• Corticosteroids carry significant risks—particularly in elderly patients—and should generally be avoided in immunocompromised patients due to increased risk of disseminated infection 1, 2

Treatment Failures and Acyclovir Resistance

Recognition of Treatment Failure

• Suspect acyclovir resistance if cutaneous lesions have not begun to resolve within 7–10 days of appropriate therapy 1
• Obtain viral culture with susceptibility testing to confirm resistance 1

Management of Confirmed Resistance

• For proven or suspected acyclovir-resistant VZV, switch to foscarnet 40 mg/kg IV every 8 hours until clinical resolution 1
• All acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir 1
• Acyclovir resistance is extremely rare in immunocompetent patients but occurs in up to 7% of immunocompromised patients 1

Infection Control and Prevention

Transmission Precautions

• Patients with active shingles should avoid contact with susceptible individuals until all lesions have fully crusted, as the virus can be transmitted via direct contact with lesions or aerosolized vesicular fluid 1
• Cover lesions with clothing or dressings to minimize transmission risk 1
• For disseminated zoster (≥3 dermatomes), implement both airborne and contact precautions in healthcare settings 1

Post-Exposure Prophylaxis

• Administer varicella-zoster immune globulin (VZIG) within 96 hours of exposure to high-risk individuals including pregnant women, immunocompromised patients, and premature newborns 1
• If VZIG is unavailable or >96 hours have passed, give a 7-day course of oral acyclovir beginning 7–10 days after exposure 1

Vaccination for Future Prevention

• The recombinant zoster vaccine (Shingrix) is strongly recommended for all adults aged ≥50 years, regardless of prior herpes zoster episodes, providing >90% efficacy in preventing future recurrences 4, 1, 2
• Vaccination should ideally occur before initiating immunosuppressive therapies but can be administered after recovery from acute shingles 4, 1
• The vaccine is a two-dose series and provides superior protection compared to the live-attenuated vaccine 4

Critical Pitfalls to Avoid

• Never use topical acyclovir—it is substantially less effective than systemic therapy and is not recommended 1, 5, 2
• Do not discontinue antiviral treatment at exactly 7 days if lesions are still forming or have not completely scabbed 1
• Avoid short-course antiviral regimens of 1–3 days designed for genital herpes, as they are inadequate for VZV infection 1
• Do not apply corticosteroid creams to active shingles lesions, as this can increase risk of severe disease and dissemination, especially in immunocompromised patients 1
• Ensure adequate hydration during systemic acyclovir or valacyclovir therapy to reduce risk of crystalluria and nephrotoxicity 1